0 99

Cited 0 times in

High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study

DC FieldValueLanguage
dc.contributor.author고영국-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author신동호-
dc.contributor.author안철민-
dc.contributor.author임의-
dc.contributor.author장양수-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.date.accessioned2018-08-28T17:15:46Z-
dc.date.available2018-08-28T17:15:46Z-
dc.date.issued2018-
dc.identifier.issn0300-8932-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162417-
dc.description.abstractINTRODUCTION AND OBJECTIVES: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. METHODS: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40mg atorvastatin, n = 1000) or low-intensity (20mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). RESULTS: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%CI, 0.36-0.92; P = .018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P = .025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P = .033) in the high-intensity statin treatment group. CONCLUSIONS: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01557075.-
dc.description.statementOfResponsibilityrestriction-
dc.languageSpanish, English(Summary)-
dc.publisherElsevier España-
dc.relation.isPartOfRevista Espanola de Cardiologia-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleHigh-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorEui Im-
dc.contributor.googleauthorYun-Hyeong Cho-
dc.contributor.googleauthorYongsung Suh-
dc.contributor.googleauthorDeok-Kyu Cho-
dc.contributor.googleauthorAe-Young Her-
dc.contributor.googleauthorYong Hoon Kim-
dc.contributor.googleauthorKyounghoon Lee-
dc.contributor.googleauthorWoong Chol Kang-
dc.contributor.googleauthorKyeong Ho Yun-
dc.contributor.googleauthorSang-Yong Yoo-
dc.contributor.googleauthorSang-Sig Cheong-
dc.contributor.googleauthorDong-Ho Shin-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorYangsoo Jang-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.identifier.doi10.1016/j.rec.2017.06.008-
dc.contributor.localIdA00127-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA02097-
dc.contributor.localIdA02269-
dc.contributor.localIdA03394-
dc.contributor.localIdA03448-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.relation.journalcodeJ02623-
dc.identifier.eissn1579-2242-
dc.identifier.pmid28716428-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1885585717303171-
dc.subject.keywordCoronary artery disease-
dc.subject.keywordDrug-eluting stent-
dc.subject.keywordEnfermedad coronaria-
dc.subject.keywordEstatina-
dc.subject.keywordStatin-
dc.subject.keywordStent farmacoactivo-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.alternativeNameKim, Byeong Keuk-
dc.contributor.alternativeNameKim, Jung Sun-
dc.contributor.alternativeNameShin, Dong Ho-
dc.contributor.alternativeNameAhn, Chul Min-
dc.contributor.alternativeNameIm, Eui-
dc.contributor.alternativeNameJang, Yang Soo-
dc.contributor.alternativeNameChoi, Dong Hoon-
dc.contributor.alternativeNameHong, Myeong Ki-
dc.contributor.affiliatedAuthorKo, Young Guk-
dc.contributor.affiliatedAuthorKim, Byeong Keuk-
dc.contributor.affiliatedAuthorKim, Jung Sun-
dc.contributor.affiliatedAuthorShin, Dong Ho-
dc.contributor.affiliatedAuthorAhn, Chul Min-
dc.contributor.affiliatedAuthorIm, Eui-
dc.contributor.affiliatedAuthorJang, Yang Soo-
dc.contributor.affiliatedAuthorChoi, Dong Hoon-
dc.contributor.affiliatedAuthorHong, Myeong Ki-
dc.citation.volume71-
dc.citation.number6-
dc.citation.startPage423-
dc.citation.endPage431-
dc.identifier.bibliographicCitationRevista Espanola de Cardiologia, Vol.71(6) : 423-431, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.